Wei Shi
Wuhan University
20 Papers
10 Citations
Wei Shi is an academic researcher from Wuhan University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 8 publications.
Chat about Author
Papers
Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: an open-label, multicenter, phase 1b trial.
Wanpu Yan,Wen-Zhao Zhong,Yan-hui Liu,Qi-Xun Chen,Wenqun Xing,Qin Zhang,Lunxu Liu,Di Ge,Ke-Neng Chen,Fan Yang,Xiang Lin,Lili Song,Wei Shi,Yi-Long Wu +13 more
TL;DR: Adebrelimab plus nab-paclitaxel and carboplatin as perioperative treatment for resectable NSCLC was evaluated in this paper , where the primary end point was major pathologic response (MPR).
23
With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II–III squamous cell carcinoma of the esophagus: A propensity score-matched analysis
Yongshun Chen,Yongshun Chen,Liying Guo,Xinyu Cheng,Jun Wang,Yougai Zhang,Yi Wang,Shaobo Ke,Wei Shi +8 more
TL;DR: Compared to CCRT alone, consolidation chemotherapy did not further prolong progression-free survival and overall survival for patients with stage II-III squamous cell carcinoma of the esophagus and the role of consolidation therapy needs to be studied further.
21
Radiotherapy plus camrelizumaband irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
Wensi Zhao,Shaobo Ke,Xiaojun Cai,Zhi Zuo,Wei Shi,Hu Qiu,Gaoke Cai,Ying Gong,Yusheng Wu,Shasha Ruan,Yongshuo Chen +10 more
TL;DR: In this paper , the authors evaluated the efficacy and safety of low-dose radiotherapy plus immunotherapy and second-line chemotherapy in oligometastatic esophageal squamous cell carcinoma (ESCC).
16
Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
Yongshun Chen,Xiaoyuan Wu,Daxuan Hao,Xinyu Cheng,Lei Zhang,Yougai Zhang,Shaobo Ke,Wei Shi,Chunyu He +8 more
TL;DR: NCRT results in improved R0 resection, higher pCR rate, and a lower frequency of lymph node metastases compared to nCT, adding nimotuzumab to nCRT is safe and appears to facilitate complete resection and increase the p CR rate.
LBA5 A phase II study of neoadjuvant SHR-1701 with or without chemotherapy (chemo) followed by surgery or radiotherapy (RT) in stage III unresectable NSCLC (uNSCLC)
Y. Wu,Q. Zhou,Xu Yang,Y. Zhao,G. Han,Qiang Pang,Z C Zhang,Qi Wang,J. Yao,H Wang,Bo Liu,Q. Chen,Xiaoqi Du,K. Q. Cai,B.G. Li,Jinquan Shuang,L. Song,Wei Shi +17 more
TL;DR: In this paper , consolidation immunotherapy (IO) after chemoradiation is the standard of care for stage III uNSCLC and the addition of IO-based induction therapy may further improve outcome.
7